Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 7/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468072 | 1.00 | GPR6 (0.36) | GPR6GPR119PDE4BCETPUTS2R | |
| SCHEMBL30468070 | 1.00 | GPR6 (0.36) | GPR6GPR119PDE4BCETPUTS2R | |
| SCHEMBL30468096 | 0.96 | GPR6 (0.35) | GPR6GPR119PDE4BCETPIRAK4 | |
| SCHEMBL30467974 | 0.93 | KDM4D (0.36) | GPR119CETPARUSP30KDM4D | |
| SCHEMBL30580202 | 0.91 | GPR6 (0.36) | GPR6UTS2R | |
| SCHEMBL26388431 | 0.87 | GPR6 (0.36) | GPR6UTS2RIRAK4USP30 | |
| SCHEMBL26388463 | 0.87 | GPR6 (0.36) | GPR6UTS2RIRAK4USP30 | |
| SCHEMBL30468056 | 0.86 | IRAK4 (0.36) | GPR6GPR119PDE4BCETPIRAK4 | |
| SCHEMBL30468020 | 0.86 | IRAK4 (0.36) | GPR6GPR119PDE4BCETPIRAK4 | |
| SCHEMBL23085662 | 0.80 | CTSS (0.36) | GPR6GPR119CETPIRAK4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4161920-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP1, USP47 | GPR6 4140/4885GPR119 4205/4885PDE4B 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.